Podcast: Expert voices – Navigating NMIBC
What does “the right care for the right patient” really mean in bladder cancer? In this 12-part podcast series, host Ashish Kamat (The University of Texas MD Anderson Cancer Center, Houston, USA) explores the clinical decisions that shape diagnosis, treatment, and follow-up – from navigating overlapping guidelines to weighing cystectomy against bladder-sparing options. Listen now for expert insights on non-muscle-invasive bladder cancer (NMIBC) you can apply directly in clinic.
Earlier episodes
Meet the host
Ashish Kamat, MD, MBBS, FACS
Dr. Ashish M. Kamat is an Endowed Professor of Urologic Oncology (Surgery) and Cancer Research, and the Director of the Bladder Cancer Support Program at University of Texas MD Anderson Cancer Center in Houston. He is the founding President of the International Bladder Cancer Group (IBCG) and serves as the Associate Cancer Center Director at the RFHNH Hospital in Mumbai. Dr. Kamat specializes in genitourinary cancers, with a particular focus on immunotherapy for urothelial cancers. He has led numerous research efforts and clinical trials in this field, resulting in over 610 publications in prestigious journals, textbooks and news articles.
Dr. Kamat's influence extends globally through his leadership in organizations such as the IBCG, the International Bladder Cancer Network (IBCN), and the Société Internationale d'Urologie (SIU). He actively contributes to organizations including the American Urologic Association (AUA), the Society of Urologic Oncology (SUO), American Society of Clinical Oncology (ASCO), and European Association of Urology (EAU), having served on their boards and played pivotal roles in organizing national and international meetings.
A dedicated educator, Dr. Kamat served as Fellowship Director at MD Anderson (2005-2016) and continues to mentor students, residents, fellows, and international visiting scholars, including via the AUA USMART Program. He serves on editorial boards of leading journals including European Urology Oncology, Urologic Oncology, Journal of Urology, Expert Reviews, and leads UroToday’s Bladder Cancer Center of Excellence.
Dr. Kamat is deeply committed to patient advocacy. In recognition of his service, the "Wayne B. Duddlesten Professorship in Honor of Dr. Ashish Kamat" was established in 2016 to advance cancer research and education at MD Anderson Cancer Center.
Disclosures: Research funding from FKD Therapies (now Ferring), the Patient Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics, and SWOG. Advisory board or consulting fees from Astellas Pharma, Atonco Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, Urogen Pharma, US Biotest, Valar Labs, and Vivet Therapeutics. Joint patent with MD Anderson Cancer Center for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy). AMK also holds/recently held leadership or fiduciary roles in the International Bladder Cancer Group (IBCG), European Urology Oncology, the Journal of Urology, UroToday, American Urological Association (AUA), and World Bladder Cancer Patient Coalition.
of interest
are looking at
saved
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.